Literature DB >> 2409200

Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.

S L Newman, L K Mikus.   

Abstract

Monoclonal antibodies were used to determine the number and molecular form of C3 bound to particulate activators of the complement (C) system by human serum. Sheep erythrocytes (E) coated with IgM (EIgM) and IgG (EIgG) were used to study activation of the classical pathway (CP). Yeast (Y), rabbit erythrocytes (ER), and five species of bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae type 3, Streptococcus pyogenes, and Hemophilus influenzae type b) were used to study activation of the alternative pathway (AP). The deposition of C3b onto EIgM and EIgG incubated in C7-deficient human serum was dependent on the serum concentration. At all serum concentrations tested, there was complete conversion of C3b to iC3b. Kinetic analysis of C3b deposition and conversion to iC3b indicated that these events occurred almost simultaneously; the reaction was completed by 15 min. The deposition of C3 onto the AP activators ER and Y was also dependent on serum concentration, and ER, but not Y, required the presence of Mg-EGTA and thus the activation of only the AP. C3b deposition and conversion to iC3b on Y was complete in 15 min, with 82% of bound C3 converted to iC3b. For ER, maximum C3 deposition required 30 min in both the presence and absence of Mg-EGTA. However, after 1 h of incubation, 74% of bound C2 was iC3b in the absence of Mg-EGTA, compared with only 52% in the presence of Mg-EGTA. Thus, even on AP activators, a large portion of C3b may be converted to iC3b, and this conversion is probably controlled by elements on the particle's surface. Studies with the five species of bacteria yielded similar results. Approximately 3-5 X 10(4) molecules of C3 were bound per microorganism, with opsonization being completed in 30 min. Remarkably, only 16-28% of bound C3 was in the form of iC3b, even after 2 h of incubation. The presence or absence of Mg-EGTA, or the addition of purified CR1 to the reaction mixture, did not significantly effect the ratio of C3b to iC3b. Finally, SDS-PAGE and autoradiography of particle-bound 125I-C3 fragments confirmed that there was no conversion of iC3b to C3d,g or C3d. The data obtained about the opsonization of bacteria suggest that the predominant form of C3 that is encountered by inflammatory phagocytes may be C3b.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409200      PMCID: PMC2187632          DOI: 10.1084/jem.161.6.1414

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

1.  Activation of the alternative complement pathway by Haemophilus influenzae type B.

Authors:  P H Quinn; F J Crosson; J A Winkelstein; E R Moxon
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

2.  Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation.

Authors:  J A Winkelstein; H S Shin; W B Wood
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS).

Authors:  D C Morrison; L F Kline
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

5.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

6.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

7.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

8.  The role of membrane receptors for C3b and C3d in phagocytosis.

Authors:  A G Ehlenberger; V Nussenzweig
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

9.  Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation.

Authors:  C Bianco; F M Griffin; S C Silverstein
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  35 in total

1.  Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.

Authors:  Ole-Lars Brekke; Bernt Christian Hellerud; Dorte Christiansen; Hilde Fure; Albert Castellheim; Erik Waage Nielsen; Anne Pharo; Julie Katrine Lindstad; Grethe Bergseth; Graham Leslie; John D Lambris; Petter Brandtzaeg; Tom Eirik Mollnes
Journal:  Mol Immunol       Date:  2011-08-11       Impact factor: 4.407

2.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

Authors:  T R Kozel; M A Wilson; G S Pfrommer; A M Schlageter
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

3.  Attachment of human polymorphonuclear leukocytes to herpes simplex virus-infected fibroblasts mediated by antibody-independent complement activation.

Authors:  J A van Strijp; K P van Kessel; L A Miltenburg; A C Fluit; J Verhoef
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Functions of the complement components C3 and C5 during sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Brian A Nadeau; Danielle E Day; Firas S Zetoune; J Vidya Sarma; Markus S Huber-Lang; Peter A Ward
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

5.  The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations.

Authors:  M Super; R J Levinsky; M W Turner
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

6.  Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Authors:  Bing Ren; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Role of complement in mouse macrophage binding of Haemophilus influenzae type b.

Authors:  G J Noel; D M Mosser; P J Edelson
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  Roles of complement and complement receptor type 3 in phagocytosis of Listeria monocytogenes by inflammatory mouse peritoneal macrophages.

Authors:  D A Drevets; P A Campbell
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

9.  Activated C3 (C3b) in the nephritic glomerulus.

Authors:  C Pan; C F Strife; A J McAdams; C D West
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

10.  Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia.

Authors:  John G Younger; Sunita Shankar-Sinha; Marc Mickiewicz; Adam S Brinkman; Gabriel A Valencia; J Vidya Sarma; Ellen M Younkin; Theodore J Standiford; Firas S Zetoune; Peter A Ward
Journal:  Am J Respir Cell Mol Biol       Date:  2003-10       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.